A new drug being trialled for treating breast cancer and diabetes has been shown to ‘melt away’ the fat inside arteries that can cause heart attacks and strokes.
Researchers from the University of Aberdeen, using pre-clinical mouse models, showed that just a single dose of the drug (Trodusquemine) completely reversed the effects of a disease that causes a host of heart problems.
Atherosclerosis is the build-up of fatty material inside the arteries.
Over time this fatty material can grow bigger until your arteries become so narrow that not enough blood can pass through.
Atherosclerosis is the condition that causes most heart attacks and strokes.
In pre-clinical tests, mice with set-in atherosclerosis, mimicking what happens in humans, had less fatty plaques in their arteries whether they had regular doses over time or just a single dose of Trodusquemine.
The drug works by stopping an enzyme called PTP1B, which is normally increased in people with obesity or diabetes and conditions involving prolonged inflammation such as sepsis, inflamed diabetic foot ulcers and allergic lung inflammation. The researchers found that it also stimulated the action of another protein (AMPK), which effectively mimics exercise and reduces chronic inflammation.
It has already been shown to be effective with diabetes and breast cancer patients but this is the first time the drug has been shown to have benefits for long-term cardiovascular disease.
The £236,000 study was funded by the British Heart Foundation.
Professor Mirela Delibegovic and Dr Dawn Thompson from the University of Aberdeen’s Institute of Medical Sciences who led the study said: “All humans have some level of atherosclerosis. As you age you start to develop these fatty streaks inside your arteries. It is a big problem for people who are overweight or have underlying cardiovascular conditions.”
“Trodusquemine has already been trialled for treatment of diabetes and breast cancer but this is the first time it has been used in models of atherosclerosis.
“These have only been tested at pre-clinical level, in mice, so far but the results were quite impressive and showed that just a single dose of this drug seemed to completely reverse the effects of arthrosclerosis.
“The next step is to test the ability of this drug to improve outcomes in human patients with developed atherosclerosis and cardiovascular disease”.
Learn more: Drug ‘melts away’ fat inside arteries
The Latest on: Atherosclerosis
[google_news title=”” keyword=”atherosclerosis ” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Vaping, even once, may raise the risk of heart failure, study findson April 27, 2024 at 4:00 am
A new study indicates that people who have used a vape at any point in their lives are 19% more likely to experience heart failure compared to people who have never used them.
- Irregular bone marrow cells may increase heart disease riskon April 26, 2024 at 4:00 am
Over time, bone marrow stem cells develop key genetic errors and pass them on to immune cells. This may increase the risk of developing heart disease.
- Exercise can ease peripheral artery disease symptomson April 25, 2024 at 12:56 pm
Patricia Creque describes herself as "one of those people who has music in my head and am always ready to dance." ...
- Can Niacin Slow the Development of Atherosclerosis in Coronary Artery Disease Patients Already Taking Statins?on April 23, 2024 at 5:00 pm
A low HDL-cholesterol level is recognized as a coronary risk factor and increases the risk of unfavorable events related to coronary atherosclerosis. Unlike for LDL cholesterol, the National ...
- Global Atherosclerosis Industry is expected to reach US$ 59,514.3 Million, growing at a consistent CAGR of 2.8% | FMIon April 23, 2024 at 8:13 am
The Global Atherosclerosis Industry is on track for significant expansion, with a projected Compound Annual Growth Rate (CAGR) of 2.8% from 2023 to 2033. This translates to a market valuation of US$59 ...
- Spanish scientists identify the key cell type for strategies to prevent atherosclerosis in progeria syndromeon April 22, 2024 at 12:21 pm
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare genetic disease that affects just 1 in every 20 million people; it is estimated that fewer than 400 children in the world have the ...
- Vascular Proliferation and Atherosclerosis: New Perspectives and Therapeutic Strategieson April 20, 2024 at 5:00 pm
In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention, as well as to the formation of the fibrous cap that provides stability ...
- Ancient Alleles Shed Light on Atherosclerosis Riskon April 19, 2024 at 7:20 am
Calculating the polygenic risk scores of ancient humans such as Ötzi the iceman helps researchers understand the genetic predisposition to cardiovascular disease.
- Atherosclerosis News and Researchon April 16, 2024 at 5:01 pm
Blockage of arterial blood vessels caused by atherosclerosis is largely responsible for heart attacks and strokes, which are the most common causes of death worldwide. University of Virginia ...
- What Is Atherosclerosis?on April 10, 2024 at 5:00 pm
Atherosclerosis is a narrowing of the arteries caused by a buildup of cholesterol plaque. It may lead to stroke, heart attacks, dementia, and other health challenges. When plaque builds up and the ...
via Google News and Bing News
